Myotonic Dystrophy - Epidemiology Forecast - 2034

Myotonic Dystrophy - Epidemiology Forecast - 2034

Key Highlights

DelveInsight's analysis indicates that there were nearly 54,068 diagnosed prevalent cases of myotonic dystrophy in the United States in 2023. Projections suggest that these cases will continue to rise, with anticipated growth reaching notable levels by 2034.

DelveInsight's analysis shows that in 2023, there were approximately 31,290 diagnosed prevalent cases of Myotonic Dystrophy Type 1 and nearly 7,270 cases of Myotonic Dystrophy Type 2 across the EU4 and the UK. These numbers are projected to rise over the forecast period (2024–2034), largely driven by enhanced awareness, which is expected to boost the diagnosed prevalence of Myotonic Dystrophy.

According to DelveInsight's analysis, in 2023 it is indicated that within the EU4 and the UK, Myotonic Dystrophy prevalence varied across age groups, with nearly 2,040 congenital cases and 4,190 infantile cases reported. Additionally, juvenile cases reached nearly 11,060, while adult-onset cases were notably higher at 14,096. Late-onset cases accounted for 7,158, highlighting a diverse distribution of Myotonic Dystrophy across age categories.

In 2023, in the US there were nearly 4,325 reported cases of Myotonic Dystrophy in children and 49,740 cases in adults, with numbers projected to increase by 2034.

In Japan in 2023, reported cases of Myotonic Dystrophy comorbidities included nearly 1,834 with gastrointestinal symptoms, 1,605 with cardiac dysrhythmias, 1,490 with organic sleep disorders, 1,452 with muscle or connective tissue issues, 1,414 with sleep disorders, 1,375 with other respiratory conditions, and 3,566 with various other comorbidities.

DelveInsight’s “Myotonic Dystrophy – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Myotonic Dystrophy, historical and forecasted epidemiology of Myotonic Dystrophy in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Myotonic Dystrophy Understanding

Myotonic Dystrophy Overview

Myotonic Dystrophy is a complex, inherited neuromuscular disorder characterized by progressive muscle wasting and weakness, especially affecting the facial, neck, and distal limb muscles. The disease manifests in two primary forms Myotonic Dystrophy Type 1 and Type 2 each differing in genetic causes, symptom severity, and age of onset. Myotonic Dystrophy Type 1 is often more severe, with earlier onset and multisystem involvement, including cardiac, respiratory, and endocrine complications. The genetic mutation behind Myotonic Dystrophy disrupts normal cell function, leading to muscle stiffness and delayed relaxation. This disorder, varying in its clinical presentation, poses considerable long-term challenges for affected individuals and caregivers.

Myotonic Dystrophy Diagnosis

Diagnosing Myotonic Dystrophy can be challenging due to its varied and often subtle symptom onset. Muscle stiffness, delayed relaxation, and facial weakness may initially appear mild, delaying diagnosis until more severe symptoms develop. The complexity further extends with distinguishing between Myotonic Dystrophy Type 1 and Type 2, requiring genetic testing for accurate classification. This condition often mimics other neuromuscular disorders, complicating differential diagnosis. Additionally, early-stage symptoms in affected individuals, particularly in those with late-onset forms, may not be readily recognized. This delay contributes to challenges in providing timely treatment and adequately managing disease progression.

Further details related to diagnosis are provided in the report…

Myotonic Dystrophy Epidemiology

For the purpose of designing the patient-based model for Myotonic Dystrophy, the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of Myotonic Dystrophy, Type-Specific Diagnosed Prevalent Cases of Myotonic Dystrophy, Type-Specific Diagnosed Prevalent Cases of Myotonic Dystrophy 1, Age-Specific Diagnosed Prevalent Cases of Myotonic Dystrophy, and Comorbidity Associated With Diagnosed Prevalent Cases of Myotonic Dystrophy in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

DelveInsight’s analyst estimate that approximately 105 thousand Diagnosed Prevalent Cases of Myotonic Dystrophy were found in 2023 in the 7MM.

As per DelveInsight’s estimates, the United States exhibited the highest diagnosed prevalent population of Myotonic Dystrophy, as compared to other 7MM countries.

As per DelveInsight’s estimations, the Total Diagnosed Prevalent Cases of Myotonic Dystrophy in Japan was around 12,735 in 2023 and is projected to increase during the forecast period owing to the increasing prevalence of smoking, improved diagnosis and increasing awareness among the patient population.

DelveInsight’s analysis indicates that in 2023, the US had approximately 43,255 diagnosed cases of Myotonic Dystrophy Type 1 and 10,815 cases of Myotonic Dystrophy Type 2. This data highlights a significant prevalence of both types in the population, underscoring the impact of Myotonic Dystrophy across diverse patient groups, with cases anticipated to rise as awareness and diagnostic efforts increase.

In 2023, DelveInsight reported a breakdown of Myotonic Dystrophy Type 1 cases in the US, with nearly 540 congenital, 3,893 infantile, 1,515 juvenile, 39,686 adult-onset, and 8,435late-onset cases. This distribution reflects the varied onset across age groups, with the adult-onset form being the most common, presenting distinct clinical management challenges at each stage.

In Japan, DelveInsight’s 2023 data shows nearly 1,565 cases of Myotonic Dystrophy among children and 11,170 cases among adults. This distribution underscores the considerable prevalence in both age groups, suggesting the need for targeted management strategies across age demographics to address varying disease impacts.

For 2023 in EU4 and the UK, DelveInsight reported nearly 5,550 cases with gastrointestinal symptoms, 4,858 with cardiac dysrhythmia, 4,510 with organic sleep disorders, 4,396 with muscle/ligament/fascia issues, 4,280 with general sleep disorders, 4,165 with other lung diseases, and 10,796 cases with other comorbidities, highlighting the disease's multisystem impact.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Department of Neurology, Virginia Commonwealth University, Richmond, US; Department of Neurology, University of Rochester Medical Center, US; Institute of Human Genetics, Julius-Maximilians-University of Würzburg, Würzburg, Germany; University Hospital of Montpellier, France; Department of Neurosciences, University of Padova, Padova, Italy; Department of Neurology, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain; Department of Neurology, Salford Royal NHS Foundation Trust, Salford, UK; Clinical Neurophysiology, Osaka University Graduate School of Medicine, Osaka, Japan; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Myotonic Dystrophy, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Diagnosed Prevalent Cases of Myotonic Dystrophy, , , Age-Specific Diagnosed Prevalent Cases of Myotonic Dystrophy, and

Myotonic Dystrophy Report Insights

Patient Population

Country-wise Epidemiology Distribution

Total Diagnosed Prevalent Cases of Myotonic Dystrophy

Type-Specific Diagnosed Prevalent Cases of Myotonic Dystrophy

Type-Specific Diagnosed Prevalent Cases of Myotonic Dystrophy 1

Age-Specific Diagnosed Prevalent Cases of Myotonic Dystrophy

Comorbidity Associated With Diagnosed Prevalent Cases of Myotonic Dystrophy

Myotonic Dystrophy Report Key Strengths

11 years Forecast

The 7MM Coverage

Myotonic Dystrophy Epidemiology Segmentation

Myotonic Dystrophy Report Assessment

Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Myotonic Dystrophy? What will be the growth opportunities across the 7MM concerning the patient population of Myotonic Dystrophy?

What is the historical and forecasted Myotonic Dystrophy patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Why is the diagnosed prevalent cases of Myotonic Dystrophy in Japan lower than the US?

Which country has a high patient share for Myotonic Dystrophy?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Myotonic Dystrophy prevalence cases in varying geographies over the coming years.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Myotonic Dystrophy Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Myotonic Dystrophy cases in 2023?

The highest cases of Myotonic Dystrophy was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Myotonic Dystrophy cases in 2023?

The highest cases of Myotonic Dystrophy were found in the US among the 7MM in 2023.